EUVIMED · CrossrefZeitschrift
Hepatology Research
ISSN 1386-6346 · Wiley
Neueste Artikel
Acknowledgment
Community‐Based Screening for Hepatitis B Virus in a Rural Japanese Population: The Nagawa Project
Comment on “The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy”
Biliary Abnormality on Imaging During Lenvatinib Plus Hepatic Arterial Infusion Chemotherapy With Cisplatin for Hepatocellular Carcinoma: A Pilot Descriptive Study
Rare Variants in PFIC‐Related Genes Among Adults With Intrahepatic Cholestasis
Potential Role of Liver Transplantation for Child–Pugh Class A Hepatocellular Carcinoma: Prognosis and Medical Expenditure in Japan—A Retrospective Single‐Center Study
Statin Use Is Associated With Improved Survival But Not Progression‐Free Outcomes in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab–Bevacizumab
Prospective Seroepidemiological Study of Hepatitis E Virus Infection in an Occupational Health‐Checkup Cohort in Mie Prefecture, Japan
Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin‐3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients With Chronic Hepatitis B
Treatment Interval as a Prognostic Marker in Patients Undergoing Repeated Curative‐Intent Local Treatment for Recurrent Hepatocellular Carcinoma
Response to the Letter Regarding “Efficacy and Safety of Hypofractionated Radiation Therapy Combined With Immunotherapy for Hepatocellular Carcinoma With Vp4 Portal Vein Tumor Thrombosis”
Response to “Comment on ‘Using Serum Creatinine‐To‐Cystatin C Ratio to Predict Sarcopenia in Patients With Liver Cirrhosis’”
Childhood Underweight and Adulthood Obesity Associated With Increased Risk of MASLD and Cirrhosis: A Prospective Cohort Study of 375,125 Adults
Simplified BALAD (BALAD‐S) Score as a Guide for First‐Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma
Survival Outcomes After Liver Resection for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma Have Improved in the Contemporary Era
Avacopan‐Associated Hepatobiliary Adverse Events and Vanishing Bile Duct Syndrome: A PMDA/JADER and FAERS Reporting‐Profile Comparison
Impact of the Number of Remaining Natural Teeth on Decompensation and Survival in Patients With Compensated Liver Cirrhosis
Pemafibrate Improves Cholestatic Markers Regardless of the Presence of Primary Biliary Cholangitis
Development of a Risk‐Estimation Model for Identifying Patients at Risk of Early Skeletal Muscle Mass Loss in Chronic Liver Disease
Stability and Variability of Symptom Burden in Primary Biliary Cholangitis: Insights From a Decade of Follow‐Up
Association Between Locomotive Syndrome and Metabolic Dysfunction‐Associated Steatotic Liver Disease in a Health Examination Cohort: A Cross‐Sectional Study
The Visceral Fat–Muscle Trade‐off in Obese Chronic Liver Disease: Insights From SMA‐Level Periportal VAT
Correction to “Multicenter, Retrospective, Cohort Study Shows Platelet Counts Predict Hepatocellular Carcinoma Development in Patients With Nonalcoholic Fatty Liver Disease”
Psoas Muscle Index in Autoimmune Hepatitis: Prognostic and Reporting Considerations
Recombinant ADAMTS13 Ameliorates Liver Injury and Improves Hepatic Microcirculation in a Murine Acute‐on‐Chronic Liver Failure Model
Issue Information
Prognostic Value of PALBI in Patients With Hepatocellular Carcinoma and Concurrent Chronic Kidney Disease: A Nomogram Development
Updated Burden and Long‐Term Projections of Chronic Hepatitis B and C in Japan: A Nationwide Markov Modeling Study
Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study
Hepatic Outcomes in Lean Versus Nonlean Metabolic Dysfunction–Associated Steatotic Liver Disease: Propensity‐Matched Cohort Study
EUVIMED